Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis
- PMID: 12965979
- DOI: 10.7326/0003-4819-139-4-200308190-00006
Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis
Abstract
Background: Angiotensin-converting enzyme (ACE) inhibitors reduce blood pressure and urine protein excretion and slow the progression of chronic kidney disease.
Purpose: To determine the levels of blood pressure and urine protein excretion associated with the lowest risk for progression of chronic kidney disease during antihypertensive therapy with and without ACE inhibitors.
Data sources: 11 randomized, controlled trials comparing the efficacy of antihypertensive regimens with or without ACE inhibitors for patients with predominantly nondiabetic kidney disease.
Study selection: MEDLINE database search for English-language studies published between 1977 and 1999.
Data extraction: Data on 1860 nondiabetic patients were pooled in a patient-level meta-analysis. Progression of kidney disease was defined as a doubling of baseline serum creatinine level or onset of kidney failure. Multivariable regression analysis was performed to assess the association of systolic and diastolic blood pressure and urine protein excretion with kidney disease progression at 22 610 patient visits.
Data synthesis: Mean duration of follow-up was 2.2 years. Kidney disease progression was documented in 311 patients. Systolic blood pressure of 110 to 129 mm Hg and urine protein excretion less than 2.0 g/d were associated with the lowest risk for kidney disease progression. Angiotensin-converting enzyme inhibitors remained beneficial after adjustment for blood pressure and urine protein excretion (relative risk, 0.67 [95% CI, 0.53 to 0.84]). The increased risk for kidney progression at higher systolic blood pressure levels was greater in patients with urine protein excretion greater than 1.0 g/d (P < 0.006).
Conclusion: Although reverse causation cannot be excluded with certainty, a systolic blood pressure goal between 110 and 129 mm Hg may be beneficial in patients with urine protein excretion greater than 1.0 g/d. Systolic blood pressure less than 110 mm Hg may be associated with a higher risk for kidney disease progression.
Comment in
-
Guiding lights for antihypertensive treatment in patients with nondiabetic chronic renal disease: proteinuria and blood pressure levels?Ann Intern Med. 2003 Aug 19;139(4):296-8. doi: 10.7326/0003-4819-139-4-200308190-00013. Ann Intern Med. 2003. PMID: 12965986 No abstract available.
-
Summaries for patients. Blood pressure and urine protein levels with the least risk for worsening kidney disease.Ann Intern Med. 2003 Aug 19;139(4):I36. doi: 10.7326/0003-4819-139-4-200308190-00002. Ann Intern Med. 2003. PMID: 12965997 No abstract available.
Similar articles
-
Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.Ann Intern Med. 2001 Jul 17;135(2):73-87. doi: 10.7326/0003-4819-135-2-200107170-00007. Ann Intern Med. 2001. PMID: 11453706
-
Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.Kidney Int. 2001 Sep;60(3):1131-40. doi: 10.1046/j.1523-1755.2001.0600031131.x. Kidney Int. 2001. PMID: 11532109 Clinical Trial.
-
The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease.Kidney Int. 2005 Jan;67(1):265-71. doi: 10.1111/j.1523-1755.2005.00077.x. Kidney Int. 2005. PMID: 15610250
-
Renoprotective effects of antihypertensive drugs.Am J Hypertens. 1999 Jan;12(1 Pt 2):19S-32S. doi: 10.1016/s0895-7061(98)00210-6. Am J Hypertens. 1999. PMID: 10077416 Review.
-
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].Presse Med. 2002 Nov 9;31(36):1714-20. Presse Med. 2002. PMID: 12467154 Review. French.
Cited by
-
Relationship between low blood pressure and renal/cardiovascular outcomes in Japanese patients with chronic kidney disease under nephrologist care: the Gonryo study.Clin Exp Nephrol. 2015 Oct;19(5):878-86. doi: 10.1007/s10157-015-1084-4. Epub 2015 Feb 4. Clin Exp Nephrol. 2015. PMID: 25648765
-
To screen or not to screen: that is not (yet) the question.Clin J Am Soc Nephrol. 2015 Apr 7;10(4):541-3. doi: 10.2215/CJN.02150215. Epub 2015 Mar 16. Clin J Am Soc Nephrol. 2015. PMID: 25779993 Free PMC article. No abstract available.
-
Impact of AT2 receptor deficiency on postnatal cardiovascular development.PLoS One. 2012;7(10):e47916. doi: 10.1371/journal.pone.0047916. Epub 2012 Oct 29. PLoS One. 2012. PMID: 23144713 Free PMC article.
-
Retarding the progression of chronic kidney disease with renin angiotensin system blockade.Indian J Nephrol. 2012 Mar;22(2):108-15. doi: 10.4103/0971-4065.97126. Indian J Nephrol. 2012. PMID: 22787312 Free PMC article.
-
Blood pressure management in hypertensive people with non-dialysis chronic kidney disease in Queensland, Australia.BMC Nephrol. 2019 Sep 4;20(1):348. doi: 10.1186/s12882-019-1532-6. BMC Nephrol. 2019. PMID: 31484506 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous